BRTX BioRestorative Therapies, Inc.

NASDAQ
$2.27

BioRestorative Therapies, Inc. (BRTX) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $2.60 per share.

Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · After Close
Earnings Whisper
-
vs ($2.60)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $8.23

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The company's core programs consist of Disc/Spine Program and Metabolic Program. Disc/Spine Program consists of cell therapy candidate, brtxDISC(TM) is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. Metabolic Program consists of ThermoStem(R), developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. BioRestorative Therapies, Inc. is based in Melville, New York.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.